Frameworks · Sector & GxP
21 CFR Part 11
21 CFR Part 11 is the US FDA's rule for electronic records and electronic signatures. It defines the controls under which electronic records are considered trustworthy and equivalent to paper.
Who it applies to
Pharmaceutical, biotechnology, medical device and other FDA-regulated organisations that keep electronic records or use electronic signatures.
Main requirements
Validation
Systems validated for accuracy, reliability and consistent intended performance.
Audit trails
Secure, computer-generated, time-stamped audit trails for record changes.
Record protection
Records protected and retrievable throughout the retention period.
Electronic signatures
Controls for signature manifestation, linking and identity verification.
How xmodo supports it
- 1
Part 11 requirements use the same control and evidence tools as your security frameworks.
- 2
Validation reports and audit-trail reviews are stored as evidence with expiry tracking.
- 3
Inspection findings run through the audit and CAPA process and close with evidence.
Related frameworks
21 CFR Part 11 shares requirements with the frameworks below. Controls you already run for any of them count towards 21 CFR Part 11 as well.
Frequently asked questions
What is 21 CFR Part 11?
It is the US FDA's rule that defines when electronic records and electronic signatures are trustworthy and equivalent to paper. It requires system validation, computer-generated audit trails, record protection and signature controls.
Which other GxP frameworks are supported?
EU GMP Annex 11, WHO GMP and PIC/S are in the library with the same tools. You can also add site-specific requirements as custom frameworks.
Can validation evidence be shared across systems?
Yes. Validation of shared infrastructure is stored once and linked to every record-system control it supports.
How are inspection findings managed?
Findings are recorded in the audit module with severity, owners and due dates, and close with evidence. Repeat findings are tracked so systemic issues are visible.